0LIF Stock Overview
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ultragenyx Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$44.08 |
| 52 Week High | US$54.48 |
| 52 Week Low | US$31.83 |
| Beta | 0.66 |
| 1 Month Change | -6.23% |
| 3 Month Change | -0.99% |
| 1 Year Change | n/a |
| 3 Year Change | -60.63% |
| 5 Year Change | n/a |
| Change since IPO | -22.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0LIF | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -14.5% | -2.3% | -0.7% |
| 1Y | n/a | -29.4% | -1.8% |
Return vs Industry: Insufficient data to determine how 0LIF performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0LIF performed against the UK Market.
Price Volatility
| 0LIF volatility | |
|---|---|
| 0LIF Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0LIF has not had significant price volatility in the past 3 months.
Volatility Over Time: 0LIF's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1,276 | Emil Kakkis | www.ultragenyx.com |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.
Ultragenyx Pharmaceutical Inc. Fundamentals Summary
| 0LIF fundamental statistics | |
|---|---|
| Market cap | US$3.63b |
| Earnings (TTM) | -US$606.64m |
| Revenue (TTM) | US$434.25m |
8.2x
P/S Ratio-5.9x
P/E RatioIs 0LIF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0LIF income statement (TTM) | |
|---|---|
| Revenue | US$434.25m |
| Cost of Revenue | US$119.74m |
| Gross Profit | US$314.51m |
| Other Expenses | US$921.15m |
| Earnings | -US$606.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.37 |
| Gross Margin | 72.43% |
| Net Profit Margin | -139.70% |
| Debt/Equity Ratio | 323.7% |
How did 0LIF perform over the long term?
See historical performance and comparison